Physician profile
Charles Chiang
NPI 1780889519
$9,133.27
in general payments reported to CMS, 2019-2025
26 companies · $3,389 in 2025
The $3,389 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2021: $18.20 · 2022: $785 · 2023: $2,413 · 2024: $2,395 · 2025: $3,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,922 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,921.78 |
| Education | $274.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $1,586.92 | 2022-2025 | Adbry |
| Abbvie INC. | $1,364.04 | 2022-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $857.43 | 2022-2025 | Dupixent |
| Incyte Corporation | $823.87 | 2022-2025 | Opzelura |
| Genzyme Corporation | $622.30 | 2022-2025 | |
| Lilly USA, LLC | $577.31 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $553.56 | 2022-2025 | Tremfya, Stelara |
| Ucb, INC. | $392.90 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $380.26 | 2022-2025 | Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $373.69 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $282.20 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $260.98 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $219.44 | 2024-2025 | Nemluvio, Dysport, Aklief |
| Pfizer INC. | $169.66 | 2023-2025 | |
| Organon LLC | $123.64 | 2025 | Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $91.60 | 2022-2025 | |
| Abbott Laboratories | $89.60 | 2019 | |
| Strata Skin Sciences, INC. | $72.15 | 2023-2025 | Xtrac |
| Almirall LLC | $55.38 | 2023-2025 | Klisyri |
| Smith+Nephew, INC. | $53.09 | 2023 | Grafix, Grafix Pl |
| Botanix Sb INC | $43.42 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.11 | 2022-2024 | Spevigo |
| Journey Medical Corporation | $37.35 | 2023 | |
| Cipher Pharmaceuticals US LLC | $30.85 | 2025 | Natroba, Spinosad |
| Janssen Pharmaceuticals, INC | $18.20 | 2021 | |
| Prugen, INC. Pharmaceuticals | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Chiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.